MCP-1 protein may contribute to failure of AV fistulas created for vascular access in dialysis patients

A protein implicated in the development of vascular diseases may also contribute to the failure of arteriovenous (AV) fistulas created for vascular access in dialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

"Our findings raise the possibility that monocyte chemoattractant protein-1 (MCP-1) may contribute to the relatively poor outcomes regarding the function and longevity of human hemodialysis AV fistulas," comments Karl A. Nath, MB.ChB (Mayo Clinic, Rochester, MN).

AV fistulas are the preferred form of access to the circulatory system in dialysis patients. They are created by a surgical procedure to connect a vein to an artery, usually in the lower arm. The use of AV fistulas, compared to other types of dialysis access, leads to fewer complications such as infections, less hospitalization of dialysis patients, and overall, a better outcome for the dialysis patient.

However, AV fistulas are prone to certain problems. About half of AV fistulas never become functional for use in dialysis, while those that do become functional have a significant failure rate. "We thus need to understand why AV fistulas do not develop, or fail to function after a relatively short period of use," says Nath.

In a series of experiments in mice, the researchers found that MCP-1—an inflammation-promoting chemokine protein—was a "critical contributor" to AV fistula failure. The failing fistulas showed increased levels of MCP-1, and of the gene that encodes it. In contrast, AV fistulas functioned much better in genetically altered mice that lacked MCP-1. In the absence of MCP-1, AV fistulas had less vein wall thickening, and the number of functional AV fistulas was substantially higher.

Take-away message: "The present study is the first…to directly demonstrate that MCP-1 critically contributes to failure of an AV fistula," the researchers write. The results are timely, because drugs that act as MCP-1 blockers are currently under development. "Such agents, when clinically available, may be considered as a possible therapeutic approach to promote the maturation of AV fistulas, and/or extend their duration of function," says Nath.

The researchers emphasize that more research will be needed to confirm whether the results of these animal experiments are relevant to AV fistulas in humans.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A promising new strategy for malaria drug development